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Abstract
Background: Syphilis prevalence in sub-Saharan Africa appears to be stable or declining but is 
still the highest globally. Ongoing sentinel surveillance in high-risk populations is necessary to 
inform management and detect changes in syphilis trends. We assessed serological syphilis 
markers among persons with sexually transmitted infections in Zimbabwe.
Methods: We studied a predominantly urban, regionally diverse group of women and men 
presenting with genital ulcer disease (GUD), women with vaginal discharge and men with urethral 
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discharge at clinics in Zimbabwe. Syphilis tests included rapid plasma reagin and the Treponema 
pallidum hemagglutination assay.
Results: Among 436 evaluable study participants, 36 (8.3%) tested positive for both rapid 
plasma reagin and Treponema pallidum hemagglutination assay: women with GUD: 19.2%, men 
with GUD: 12.6%, women with vaginal discharge: 5.7% and men with urethral discharge: 1.5% (P 
< 0.0001).
Conclusions: Syphilis rates in Zimbabwe are high in sentinel populations, especially men and 
women with GUD.
Syphilis continues to be a major global public health problem. According to the World 
Health Organization syphilis prevalence and incidence rates are highest in the Africa region. 
Of the estimated 5.6 million incident syphilis cases that occurred worldwide in 2012, 32% 
were in Sub-Saharan Africa.1 In that same year, an estimated 930,000 maternal syphilis 
infections caused 350,000 adverse pregnancy outcomes, including 143,000 early fetal deaths 
and stillbirths, 62,000 neonatal deaths, 44,000 preterm or low weight births, and 102,000 
infected infants worldwide.2 However, contemporary studies suggest that syphilis prevalence 
may be declining in southern Africa.
In Zimbabwe, a recent modeling study based on antenatal surveys and annual program data 
estimated that national syphilis prevalence among men and women declined from 1.9% in 
2000 to 1.5% in 2016, although this decrease was not statistically signficant.3 A household-
based national survey conducted in Zimbabwe in 2015 to 2016 estimated the prevalence of 
active syphilis at 0.8%, whereas 2.7% had ever experienced infection.4 Despite the possible 
decline in prevalence, these rates are 10 times higher than the global average1 and also do 
not necessarily represent trends in high-risk populations, including persons presenting with 
sexually transmitted infection (STI)-related syndromes.
Studies from sentinel sites frequented by populations at high risk for STIs are important to 
inform epidemiologic trends. Thus, in a recent study conducted in six STI clinics in 
Zimbabwe, we found that 16% of genital ulcer disease (GUD) presentations among men and 
women was caused by Treponema pallidum, as evidenced through use of a multiplex 
polymerase chain reaction (m-PCR) assay of lesion specimens.5 These rates were similar to 
those from a recently completed study in neighboring Zambia,6 but substantially higher than 
rates from studies conducted more than 10 years ago in comparable populations in Botswana 
(5.1%),7 Malawi (6%),8 Mozambique (0%),9 and South Africa (4.9%).10 Furthermore, in 
our study, an additional 8% of GUD patients had negative m-PCR results, but both positive 
T. pallidum hemagglutination assay (TPHA) and positive rapid plasma reagin (RPR) test 
results, suggesting that up to 24% of GUD cases may have been associated with T. pallidum 
infection.5
The primary objective of this study was to further evaluate syphilis prevalence among 
persons presenting with STIs in Zimbabwe by assessing syphilis serological markers among 
all patients included in our study, thus including men presenting with urethral discharge and 
women presenting with vaginal discharge.
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METHODS
The Zimbabwe STI Etiology Study was conducted in six primarily urban, regionally diverse 
STI clinics in Zimbabwe in 2014 to 2015. The study involved the enrollment of 600 
participants; 200 women presenting with vaginal discharge, 200 men with urethral 
discharge, and 100 women and 100 men presenting with GUD. Based on statistical 
considerations detailed in the study protocol available online11 and the limited resources 
available to the study, we felt that these sample sizes would strike an acceptable balance 
between available study resources and the need for precision.
Study methods are detailed in the study protocol and an article describing the study design, 
methods and population, both available online.11,12 In addition, study outcome data have 
recently been published, including the etiology of GUD,5 the etiologies of male urethral 
discharge13 and vaginal discharge in women,14 and a manuscript detailing the prevalence of 
human immunodeficiency virus (HIV) infection in this population.15
Although syphilis results among patients presenting with GUD in this study have been 
reported previously5 we have included some of these data in this article to allow for 
comparisons with the other diagnostic groups.
The following methodological details are pertinent to this study.
Participant Recruitment and Specimen Collection
A team of three nurses was trained in study procedures and deployed sequentially for a 
period of 10 to 17 weeks to each of the six study sites, starting in two Harare clinics (Mbare 
and Budiriro), then moving to two clinics in Bulawayo (Khami Road and Nkulumane) and 
finally to clinics in Beitbridge (Dulibadzimu) and Gutu (Gutu Rural Hospital). These clinics 
were selected based on regional diversity and high rates of reported STI syndromes, 
including vaginal discharge in women, urethral discharge in men and GUD in women and 
men. The start of enrollment at each site was preceded by at least two site visits involving 
the study leadership of the team lead, the lead consultant, and senior officials representing 
the Zimbabwe Ministry of Health and Child Care.
Consecutive patients presenting with urethral discharge (men), vaginal discharge (women) 
and GUD (women and men) were enrolled in the study after obtaining informed consent. A 
paper-copy questionnaire was administered and completed by the study nurse. Information 
captured included demographic information, sexual history covering the previous 3 months 
(number of sex partners, condom use, sex work and sex with a sex worker) description of 
symptoms, history of STI/HIV, and current use of antimicrobials. GUD patients had swab 
specimens taken from the ulcer bases. Vaginal swabs for women and urine samples for men 
were obtained for chlamydia and gonorrhea testing. Blood specimens were collected from 
patients for syphilis serology and HIV testing. A separate consent for HIV testing was 
obtained. Declining a blood draw was not a reason for exclusion from the study. HIV results 
for this study have been published elsewhere.15
Rietmeijer et al. Page 3
Sex Transm Dis. Author manuscript; available in PMC 2019 December 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Patients who reported to have taken antimicrobial medication in the past 4 weeks, who were 
unable to provide consent, or who had been enrolled in the study previously were not 
eligible for study enrollment.
All patients were treated for their presenting STI syndrome according to the 2013 Zimbabwe 
STI syndromic management guidelines (see Box).16
Laboratory Procedures
All specimens were kept refrigerated after collection and shipped in a cooler box with 
cooling packs by overnight courier to the study laboratory at Wilkins Hospital in Harare, 
where they were kept refrigerated until further processing. All syphilis tests were conducted 
at the study laboratory. Syphilis serology included both treponemal and nontreponemal tests, 
TPHA and RPR, respectively (both SPINREACT, Girona, Spain). The RPR-positive samples 
were subsequently titrated up to 1:32 dilution for quantitative analysis.
All tests were performed according to test package inserts.
Ulcer samples were stored at −70°C and batched for shipment to the STI reference 
laboratory at the Centre for HIV and STIs of the National Institute of Communicable 
Diseases in Johannesburg, South Africa. Using m-PCR on a RotorGene platform(Corbett 
Research, Sydney Australia), samples were tested for the presence of Treponema pallidum, 
Haemophilus ducreyi, herpes simplex virus, and Chlamydia trachomatis strains associated 
with lymphogranuloma venereum.
We defined potentially “active” syphilis as reactivity on both treponemal (TPHA) and 
nontreponemal (RPR) tests with titers of 1:8 or greater, or an m-PCR test positive for T. 
pallidum regardless of serological test results among patients with GUD.
Vaginal and urine samples were shipped to two local laboratories and tested for N. 
gonorrhoeae and C. trachomatis by nucleic acid amplification testing using Becton 
Dickenson ProbeTec (BD Molecular Diagnostics, Franklin Lakes, NJ) at the University of 
Zimbabwe/ University of California San Francisco laboratory in the Obstetrics and 
Gynecology Department of the University of Zimbabwe School of Medicine and using 
GeneXpert (Cepheid, Sunnyvale, CA) at the Flowcytometry Laboratory in Harare. All 
testings were done according to test package inserts under standard operating procedures. 
All urine and vaginal specimens were tested on both platforms with greater than 95% 
concordance of test results.17 For the purposes of this study, we considered a chlamydia or 
gonorrhea test result to be positive when it was positive on either platform.
Human immunodeficiency virus testing followed the algorithm promoted by the Zimbabwe 
Ministry of Health and Child Care and routinely employed nationwide: an initial test by 
First Response HIV1–2-O (Premier Medical Corporation, Daman, India); if positive, a 
confirmatory Alere Determine HIV1/2 test (Alere Inc. Waltham, MA); and, in case of 
discrepancy between these results, an INSTI HIV1/HIV2 test (bioLytical Laboratories Inc. 
Richmond, BC, Canada) as tie breaker.
More detail on laboratory procedures can be found in the online supplement.12
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Data Management and Statistical Methods
After completion of the visit, questionnaire data were reviewed by the lead study nurse and 
then transcribed into a computer-based data system on handheld devices. Data were 
uploaded daily from study sites to an online secure central database.
Data were analyzed using SAS software (Cary, NC). Tests for statistical significance 
included the χ2 test for categorical variables and Student t test for continuous variables with 
P values of 0.05 or less, indicating statistical significance.
Given the purposive and selective rather than random nature of sampling in our study, the 
provision of 95% confidence intervals would convey a level of precision to the study data 
that is not supported by the study methods, and we have therefore omitted them from the 
results.
Institutional Review
The protocol, including consent forms and questionnaires, was reviewed and approved by 
the Joint Research and Ethics Committee of Parirenyatwa Central Hospital, the Zimbabwe 
Medical Research Council and the US Centers for Disease Control and Prevention.
RESULTS
Of the 600women andmen enrolled in the study,494 (82.3%) agreed to submit a blood 
sample for syphilis testing. Women and men with GUD were more likely to submit blood 
samples for testing (90.5%) than women and men with vaginal and urethral discharge 
respectively (78.3%, P < 0.001) and participants recruited at the Dulibadzimu (66.7%) and 
Budiriro (80.0%) sites were less likely to submit a sample than other clinics (P < 0.0001).
Samples of 436 participants were successfully tested by both TPHA and RPR, including 138 
women with vaginal discharge, 133 men with urethral discharge, and 78 women and 87 men 
with GUD, respectively. The remainder of the report is limited to this group.
Treponemal and Nontreponemal Test Results
TPHA and RPR results are summarized in Table 1. Thirtysix (8.3%) patients tested positive 
on both tests. In addition, 35 (8.0%) were positive on TPHA and negative on RPR, whereas 
14 (3.2%) were positive on RPR, but negative on TPHA. Both tests were negative for 351 
(80.5%) patients. Among patients with combined TPHA/RPR-positive results, 29 (80.6%) of 
36 patients had RPR titers of 1:8 or greater.
Women and men with GUD had the highest prevalence of dual positive results (respectively, 
19.2% and 12.6%, P=NS). Combined, men and women with GUD had significantly higher 
dual TPHA/RPR positivity than the combination of men with urethral discharge and women 
with vaginal discharge (15.8% vs. 3.7%, P < 0.0001). Women with vaginal discharge had 
higher combined positivity than men with urethral discharge (5.7% vs. 1.5%, P = 0.06, Table 
1).
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We did not find any associations between combined TPHA/ RPR positivity and demographic 
(gender, ethnicity, age) or behavioral risk factors, including number of sex partners, being or 
having sex with a sex worker, or condom use (data not shown). In addition, the prevalence of 
combined TPHA/RPR positivity was similar among those with (17 [10.8%] of 158) or 
without (19 [6.8%] of 278) gonorrhea (P = 0.1) and with (6 [6.9%] of 87) or without (30 
[8.6%] of 349) chlamydia infections (P = 0.6). However, persons testing positive for HIV 
had a higher TPHA/RPR positivity prevalence (23 [12.7%] of 181) than those testing 
negative for HIV (13 [5.2%] of 250, P < 0.01).
Among the women and men with GUD, 27 (16.4%) of 165 had an m-PCR result positive for 
T. pallidum. Of these 15 (55.6%) tested positive for both TPHA and RPR, and all of these 
had an RPR titer of 1:8 or greater. In addition, 6 (22.2%), tested positive for TPHA but 
negative for RPR, and 4 (14.8%) tested positive for RPR but negative for TPHA (all ≥1:8), 
whereas another 2 (7.4%) tested negative for both. Among 138 persons with GUD testing 
negative for T. pallidum on m-PCR, TPHA was positive for 21 (15.2%) and a combined 
TPHA/RPR positivity was higher (8.0%)in this group compared with women with vaginal 
discharge or men with urethral discharge (3.7%, P < 0.06).
Five of 8 patients with a history of syphilis had a positive TPHA, of which two also had a 
positive RPR. Conversely, among patients with both positive TPHA and RPR, only 2 of 36 
had a history of syphilis of which one had an RPR titer of 1:8 or greater. No records were 
available to verify previous syphilis history.
DISCUSSION
In our study of 436 patients presenting with various STI syndromes to six, primarily urban, 
STI clinics in Zimbabwe, we found evidence of current or past syphilis among 77 (17.7%), 
including 36 with TPHA/RPR dual positivity, 35 positive on TPHA and negative on RPR, 
and 6 with evidence of syphilis by m-PCR who were TPHA negative.
As expected, men and women with GUD had the highest syphilis prevalence with 48 
(29.1%) of 165 showing evidence of the infection, including 27 with primary syphilis 
diagnosed by PCR and 21 negative on PCR, but positive on TPHA. In our view, these 
findings support the continued use of syndromic management for patients with GUD in 
Zimbabwe (see Box), in the absence of more widespread syphilis testing.
The combined TPHA and RPR positivity rates among women with vaginal discharge (5.7%) 
and men with urethral discharge (1.5%) may not warrant a change in the syndromic 
management of men and women with genital discharge syndromes to treat them 
presumptively for syphilis. Moreover, the antimicrobial components of syndromic 
management for these conditions may have some effect on (incubating) syphilis. However, 
these rates are high enough to continue to emphasize syphilis testing in these populations, 
especially among women given potential risk for pregnancy and vertical transmission.
In the presence of a positive treponemal test, RPR titers of ≥1:8 are often considered to be 
indicative of active, recently acquired syphilis, where lower titers or negative nontreponemal 
test results are thought to represent longer standing or treated infections.18 However, as our 
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data show, such a distinction is arbitrary and of dubious clinical benefit, especially among 
patients with GUD. Of patients with PCR-proven (primary) syphilis, only 15 (55.6%) of 27 
had RPR titers ≥1:8 in addition to a positive TPHA. By contrast, among 21 TPHA positive 
GUD patients with low-titer or negative RPR, six (28.6%) had PCR-proven primary syphilis 
(all RPR negative) and only two gave a history of syphilis.
A positive RPR in the absence of a positive TPHA or other treponemal test is typically 
interpreted as a biological false positive result. However, 4 (14.8%) of 27 patients with PCR-
proven primary syphilis had RPR titers ≥1:8 but negative TPHA.
Thus, assessment of infection on the basis of serological interpretation is problematic and 
any person with positive treponemal and nontreponemal test results, regardless of titer, 
should be subject to careful history taking, clinical assessment and further diagnostic testing 
to determine syphilis stage and treatment duration.19
The most important limitation of this study is that it was based on a purposive sample of 
clinics in three urban regions in Zimbabwe and the results cannot be generalized to other 
regions inside and outside the country.
In addition, test performance may have been a limiting factor. In our study, tests were 
conducted by an experienced laboratorian who over the years had been the laboratory lead 
for a number of HIV prevention studies that involved collection and testing of a variety of 
STI tests, including RPR and TPHA testing. Nonetheless, possible laboratory errors cannot 
be ruled out, especially for tests that require subjective interpretation from a laboratorian. In 
a recent study, for example, Hamill et al. reported considerable variability in the 
interpretation of RPR results among four laboratories in Uganda.20
Traditional syphilis testing based on RPR screening followed by TPHA or other treponemal 
test confirmation has important limitations beyond potentially missed infections, especially 
loss to follow-up and treatment. In recent years, rapid point of care treponemal tests have 
become increasingly available in sub-Saharan Africa,21 and, despite some performance 
limitations can potentially reduce the time from diagnosis to treatment.22
Whether the high rates of positive syphilis tests, especially among men and women with 
GUD in our study represent an increase in syphilis rates in Zimbabwe is unclear. The 
previously cited3 study by Korenromp et al. suggests a decreasing incidence of syphilis in 
Zimbabwe and other studies have shown similar stable or decreasing rates in Zimbabwe4 
and other parts of southern Africa.23 However, these estimates largely rely on studies among 
pregnant women accessing antenatal care or population-based studies that have been 
performed several years ago, and may lag increases in sentinel populations like those 
recruited in our study. In the United States, for example, increasing syphilis rates among 
men who have sex with men were reported for selected, high-risk populations over 15 years 
ago,24,25 but the general population effects, including increases among heterosexual men 
and women and subsequent rises in congenital syphilis cases were only recently realized.26
With these considerations in mind, the prevalence of TPHA and RPR positivity among the 
three sentinel populations in this study warrants ongoing vigilance to the potential of a 
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syphilis resurgence in Zimbabwe and other sub-Saharan countries and supports efforts to 
continue strengthening programs for syphilis surveillance, prevention and clinical 
management.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STI Syndromic Management in Zimbabwe (as used in this study)
Women with Vaginal Discharge
Kanamycin 2 g intramuscularly single dose – plus:
Doxycycline 100 mg orally twice daily for 7 days – plus:
Metronidazole 500 mg orally three times daily for 7 days
Men with Urethral Discharge
Kanamycin 2 g intramuscularly single dose – plus:
Doxycycline 100 mg orally twice daily for 7 days
Women and Men with GUD
Benzathine Penicillin G 2.4 Million Units intramuscularly single dose – plus:
Erythromycin 500 mg orally four times a day for 7 days – plus:
Acyclovir 200 mg orally five times a day for 7 days.
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